本文選題：水通道蛋白 + 多烯磷脂酰膽堿��； 參考：《第三軍醫(yī)大學(xué)學(xué)報》2017年18期

【摘要】：目的分析非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)患者肝組織水通道蛋白(aquaporin,AQPs)3、7、9表達水平對多烯磷脂酰膽堿(plyene posphatidyl coline,PPC)療效的影響。方法分析2014-2016年本院收治的NAFLD患者87例,按病程分組:肝硬化組(n=30),肝纖維化組(n=24),肝炎組(n=33);超聲療效評估分組:有效組和無效組。隨訪不同病程的NAFLD患者PPC治療前后的肝功能酶變化,按照PPC療效進行分組,比較患者肝組織AQP3、7、9蛋白的表達差異,并進一步分析PPC療效與AQPs表達水平的相關(guān)性。結(jié)果 PPC對NAFLD患者治療整體有效率35.63%,PPC對NAFLD療效與病程嚴重程度無關(guān),但與超聲的評分密切相關(guān),表現(xiàn)為按照超聲評分有效和無效分組的不同病程組患者的谷丙轉(zhuǎn)氨酶(ALT)在PPC治療后,在每種病程患者中差異有統(tǒng)計學(xué)意義,且ALT在PPC治療后,其變化程度與超聲的變化程度呈正相關(guān),肝硬化組(R=0.780,P0.01),肝纖維化組(R=0.879,P0.01),肝炎組最高(R=0.900,P0.01)。PPC治療NAFLD效果與患者初始的肝組織AQPs的表達存在相關(guān)性:NAFLD患者肝組織AQP7、9表達量與肝功能酶的變化量呈正相關(guān)(AQP9:R=0.972,AQP7:R=0.537),而AQP3的表達水平與肝功能酶的變化量呈負相關(guān)(R=-0.881);AQP7、9表達量與超聲評分的變化量呈正相關(guān)(AQP9:R=0.763,AQP7:R=0.311),而AQP3的表達水平與肝功能酶的變化量呈負相關(guān)(R=-0.795)。結(jié)論多烯磷脂酰膽堿對非酒精性脂肪性肝病的療效與水通道蛋白表達差異密切相關(guān),提示AQPs表達水平可能影響PPC療效。
[Abstract]:Objective to investigate the effect of aquaporinus aquaporin (aquaporin) on the therapeutic effect of polyphosphatidylcholine (PPC) plyene posphatidyl in the liver tissue of patients with nonalcoholic fatty liver disease (NAF LDD). Methods Eighty-seven patients with NAFLD from 2014-2016 were divided into three groups: liver cirrhosis group (n = 30), hepatic fibrosis group (n = 24), hepatitis group (n = 33) and ultrasonic evaluation group: effective group (n = 30) and ineffective group (n = 30). Liver function enzyme changes of NAFLD patients with different course of disease were followed up before and after PPC treatment. According to the effect of PPC, the difference of expression of AQP3O7P9 protein in liver tissue was compared, and the correlation between PPC efficacy and AQPs expression level was further analyzed. Results the overall effective rate of PPC in the treatment of NAFLD patients was 35.63%. The curative effect of NAFLD was not related to the severity of the course of disease, but was closely related to the score of ultrasound. The results showed that there were significant differences in alt between the patients with different course of disease and the patients with different course of disease according to the effective and ineffective ultrasound scores after PPC treatment, and the difference of ALT after PPC treatment was statistically significant in each course of the patients, and there was no significant difference between the two groups after PPC treatment. There was a positive correlation between the degree of change and the degree of ultrasound. There was a positive correlation between the expression of AQP7O9 in liver tissues of patients with liver cirrhosis and the changes of liver function enzymes in liver tissues of patients with liver fibrosis and the expression of AQPs in liver tissues of patients with liver fibrosis, while the expression of AQP3 was water in the expression of AQP3 in the liver tissues of the patients with liver fibrosis (P < 0.05) and liver fibrosis group (n = 0.879). The highest effect of RPPC in the treatment of NAFLD was found in the patients with liver cirrhosis. There was a positive correlation between the expression of AQP7O9 in liver tissues and the changes of liver function enzymes in the patients with liver fibrosis, while the expression of AQP3 in the liver tissues was positively correlated with the expression of AQPs in the liver tissues of the patients with liver fibrosis. There was a negative correlation between the expression of AQP7H9 and the changes of liver function enzymes. There was a positive correlation between the expression of AQP9: RP9: AQP7: R7: R3, and a negative correlation between the expression level of AQP3 and the changes of liver function enzymes. Conclusion the therapeutic effect of polyenylphosphatidylcholine on non-alcoholic fatty liver disease is closely related to the difference of aquaporin expression, suggesting that the expression level of AQPs may affect the curative effect of PPC.
【作者單位】： 成都軍區(qū)總醫(yī)院消化內(nèi)科;成都軍區(qū)總醫(yī)院檢驗科;
【基金】：四川省衛(wèi)生廳資助項目(120572)~~
【分類號】：R575.5

【相似文獻】

相關(guān)期刊論文 前10條

1 鄔亞妙;;多烯磷脂酰膽堿治療非酒精性脂肪性肝病32例[J];中國藥業(yè);2008年11期

2 董坤;;左卡尼汀聯(lián)合多烯磷脂酰膽堿治療非酒精性脂肪性肝炎的療效觀察[J];臨床肝膽病雜志;2009年04期

3 魏春山;唐海鴻;童光東;;疏肝消脂方聯(lián)合多烯磷脂酰膽堿治療非酒精性脂肪性肝炎36例臨床研究[J];江蘇中醫(yī)藥;2013年07期

4 李康;劉旭明;;多烯磷脂酰膽堿聯(lián)合托尼奈酸治療非酒精性脂肪性肝炎療效觀察[J];肝臟;2013年12期

5 劉宇瓊;;多烯磷脂酰膽堿治療非酒精性脂肪性肝病的臨床價值分析[J];中國實用醫(yī)藥;2014年11期

6 莊學(xué)山;張志堅;;熊去氧膽酸聯(lián)合多烯磷脂酰膽堿治療非酒精性脂肪性肝炎療效觀察[J];中國實用醫(yī)藥;2009年10期

7 楊秀平;周長慧;;多烯磷脂酰膽堿治療非酒精性脂肪性肝炎療效觀察[J];吉林醫(yī)學(xué);2009年15期

8 陸萬竹;張青;;多烯磷脂酰膽堿治療非酒精性脂肪性肝病74例[J];中國中醫(yī)藥現(xiàn)代遠程教育;2010年01期

9 郭秀麗;梁丕霞;徐有青;;甘草酸二銨與多烯磷脂酰膽堿治療非酒精性脂肪性肝炎的療效比較[J];中國新藥雜志;2012年03期

10 王鳳俊;;多烯磷脂酰膽堿治療非酒精性脂肪性肝病的療效觀察[J];肝臟;2012年05期

相關(guān)會議論文 前6條

1 牛衛(wèi)理;趙明志;侯瑞芳;;多烯磷脂酰膽堿聯(lián)合肝病治療儀治療非酒精性脂肪性肝炎療效分析[A];中華中醫(yī)藥學(xué)會全國第十四次肝膽病學(xué)術(shù)會議論文匯編[C];2010年

2 牛衛(wèi)理;趙明志;侯瑞芳;;多烯磷脂酰膽堿聯(lián)合肝病治療儀治療非酒精性脂肪性肝炎療效分析[A];中華中醫(yī)藥學(xué)會全國第十四次肝膽病學(xué)術(shù)會議論文匯編[C];2010年

3 江慶瀾;李瑜元;;多烯磷脂酰膽堿干預(yù)與非酒精性脂肪肝大鼠基因表達水平的變化[A];中華醫(yī)學(xué)會第七次全國消化病學(xué)術(shù)會議論文匯編（下冊）[C];2007年

4 傅萍;;多烯磷脂酰膽堿聯(lián)合丹參多酚酸鈉治療酒精性肝病30例觀察[A];中華中醫(yī)藥學(xué)會脾胃病分會第二十三次全國脾胃病學(xué)術(shù)交流會論文匯編[C];2011年

5 胡振斌;邱華;官志杰;毛德文;;多烯磷脂酰膽堿聯(lián)合血塞通治療酒精性脂肪肝的臨床療效觀察[A];第十八次全國中西醫(yī)結(jié)合肝病學(xué)術(shù)會議論文匯編[C];2009年

6 張幫杰;趙迪;杜鵬程;王素娟;王慶治;;多烯磷脂酰膽堿聯(lián)合水飛薊賓治療非酒精性肝病68例臨床觀察[A];中華醫(yī)學(xué)會第十六次全國病毒性肝炎及肝病學(xué)術(shù)會議論文匯編[C];2013年

相關(guān)重要報紙文章 前1條

1 ;為肝臟加滿油[N];醫(yī)藥經(jīng)濟報;2005年

相關(guān)碩士學(xué)位論文 前1條

1 江依勇;微生態(tài)制劑聯(lián)合多烯磷脂酰膽堿治療非酒精性脂肪肝病臨床研究[D];南華大學(xué);2015年

，

本文編號：1855508